The success rate of hepatitis B blockade can reach more than 95%. So-called hepatitis B blockade means that pregnant women with relatively high hepatitis B virus, usually greater than 10^6cop/ml and normal liver function, are blocked with oral antiviral medication around 6-7 months of pregnancy, with tenbivudine or tenofovir generally recommended for treatment. After the birth of the baby, hepatitis B vaccine and hepatitis B immunoglobulin are administered. This treatment can block more than 95% of mother-to-child transmission, and there is little chance of reinfection with hepatitis B. Pregnant women can stop taking oral antiviral drugs for about 1-3 months after the birth of the baby.